Call us today for help! (214) 295-5011
This is a question that Dr. Carolyn McIntyre, a scientist at Australia’s Edith Cowan University; Professor Gary Lee of Sir Charles Gairdner Hospital, a renowned authority in mesothelioma throughout the world; and Professor Rob Newton, an expert in exercise as medicine for cancer, will study over the next three years. Health of patients with lung …
A new drug in the treatment arsenal for mesothelioma is always welcomed. Recently, an Orphan Drug Designation was granted by the US Food and Drug Administration for tremelimumab, an anti-CTLA-4 monoclonal antibody. Robert Iannone, Senior Vice President and Head of Immuno-oncology, Global Medicines Development at AstraZeneca announced, “There is a significant need for new treatment …
Geologists are primarily known for studying rocks and earth activities, such as volcanoes and earthquakes. Now geologists are also studying the connection between living organisms and earth materials. Two men, Steven Lower and Eric Taylor, began experimenting with one segment of this new sub field of geology in Lower’s lab at Ohio State University. What drives …
Eisai, and its subsidiary Morphotek, discovered and have developed an investigational monoclonal antibody amatuximab. This drug “has a high affinity and specificity for mesothelin, a protein which is overexpressed in people with malignant mesothelioma.” The European Commission has granted this antibody an orphan drug designation (ODD). This designation is for medicines developed for the diagnosis, …
U.S. Navy veterans serving from World War II through Vietnam faced a toxic threat from the asbestos aboard their own ships. Many decades later that exposure surfaced in the form of asbestos-related diseases. Of the 2,500 to 3,000 Americans diagnosed annually with malignant mesothelioma, a significant percentage of those individuals served in the U.S. Navy. Still …
